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American Medical Directors Association, Columbia, MDThe American Medical Directors AssociationdDedicated to Long
Term Care Medicine (AMDA) was pleased to partner with the
American Board of Internal Medicine (ABIM) Foundation’s Choosing
Wisely Campaign to help physicians, patients, and other health care
stakeholders think about and discuss the overuse of health care
resources in the United States. The national campaign aims to help
patients take a more involved role in their health care by learning to
choose medical tests and treatments that are supported by scientiﬁc
evidence, are not duplicative of past tests or procedures, and are truly
necessary for diagnosis or treatment.
To create the list, AMDA convened a work group made up of
members from the Clinical Practice Committee (CPC). Members of the
CPC include board-certiﬁed geriatricians; certiﬁed medical directors;
multifacility medical directors; attending practitioners; physicians
practicing in both ofﬁce-based and nursing facility practice; physi-
cians in rural, suburban, and academic settings; physicians with
university appointments; and more. It was important to AMDA that
the workgroup chosen represented the core base of the AMDA
membership. Ideas for the “5 things” were solicited from the work-
group. Suggested elements were considered for appropriateness,
relevance to the core of the specialty, and opportunities to improve
patient care. They were further reﬁned to maximize impact and
eliminate overlap, and then ranked in order of potential importance
both for the specialty and for the public. A literature search was
conducted to provide supporting evidence or to refute the activities.
The list was modiﬁed and a second round of selection of the reﬁned
list was sent to the workgroup for paring down to the ﬁnal “top 5”
list. Finally, the workgroup chose its top 5 recommendations before
submitting a ﬁnal draft to the AMDA Executive Committee, which
was then approved.The Top Five Items Physicians and Patients Should Question in
the Long Term Care Setting
The following are the top 5 items that were selected. The rationale
for each item follows.
Item 1. Don’t insert percutaneous feeding tubes in individuals
with advanced dementia. Instead, offer oral assisted feedings.1e10The author declares no conﬂicts of interest.
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http://dx.doi.org/10.1016/j.jamda.2013.07.004Rationale: Strong evidence exists that artiﬁcial nutrition does not
prolong life or improve quality of life in patients with advanced
dementia. Substantial functional decline and recurrent or progressive
medical illnesses may indicate that a patient who is not eating is
unlikely to obtain any signiﬁcant or long term beneﬁt from artiﬁcial
nutrition. Feeding tubes are often placed after hospitalization,
frequently with concerns for aspirations, and for those who are not
eating. Contrary to what many people think, tube feeding does not
ensure the patient’s comfort or reduce suffering; it may cause ﬂuid
overload, diarrhea, abdominal pain, local complications, and less
human interaction and may increase the risk of aspiration. Assistance
with oral feeding is an evidence-based approach to provide nutrition
for patients with advanced dementia and feeding problems.
Item 2. Don’t use Sliding Scale Insulin for long-term diabetes
management for individuals residing in the nursing home.11e20
Rationale: Sliding Scale Insulin (SSI) is a reactive way of treating
hyperglycemia after it has occurred rather than preventing it. Good
evidence exists that SSI is neither effective in meeting the body’s
insulin needs nor is it efﬁcient in the long term care (LTC) setting. Use
of SSI leads to greater patient discomfort and increased nursing time
because patients’ blood glucose levels are usually monitored more
frequently than may be necessary and more insulin injections may be
given. With SSI regimens, patients may be at risk from prolonged
periods of hyperglycemia. In addition, the risk of hypoglycemia is
a signiﬁcant concern because insulin may be administered without
regard to meal intake. Basal insulin, or basal plus rapid-acting insulin
with one or more meals (often called basal/bolus insulin therapy)
most closely mimics normal physiologic insulin production and
controls blood glucose more effectively.
Item 3. Don’t obtain a urine culture unless there are clear signs
and symptoms that localize to the urinary tract.21e32
Rationale: Chronic asymptomatic bacteriuria is frequent in the LTC
setting, with prevalence as high as 50%. A positive urine culture in the
absence of localized urinary tract infection (UTI) symptoms (ie,
dysuria, frequency, urgency) is of limited value in identifying whether
a patient’s symptoms are caused by a UTI. Colonization (a positive
bacterial culture without signs or symptoms of a localized UTI) is
a common problem in LTC facilities that contributes to the overuse of
antibiotic therapy in this setting, leading to an increased risk of
diarrhea, resistant organisms, and infection due to Clostridium difﬁ-
cile. An additional concern is that the ﬁnding of asymptomatic
bacteriuria may lead to an erroneous assumption that a UTI is the
cause of an acute change of status, hence failing to detect or delaying
the more timely detection of the patient’s more serious underlying
problem. A patient with advanced dementia may be unable to reporttion, Inc.
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culture if there are signs of systemic infection, such as fever (increase
in temperature of equal to or greater than 2F [1.1C] from baseline),
leukocytosis, or a left shift or chills, in the absence of additional
symptoms (eg, new cough) to suggest an alternative source of
infection.
Item 4. Don’t prescribe antipsychotic medications for behavioral
and psychological symptoms of dementia (BPSD) in individuals with
dementia without an assessment for an underlying cause of the
behavior.21,33e46
Rationale: Careful differentiation of cause of the symptoms
(physical or neurological versus psychiatric, psychological) may help
better deﬁne appropriate treatment options. The therapeutic goal of
the use of antipsychotic medications is to treat patients who present
an imminent threat of harm to self or others, or are in extreme
distress, not to treat nonspeciﬁc agitation or other forms of lesser
distress. Treatment of BPSD in association with the likelihood of
imminent harm to self or others includes assessing for and identi-
fying and treating underlying causes (including pain, constipation,
and environmental factors, such as noise, being too cold or warm, and
so forth), ensuring safety, reducing distress, and supporting the
patient’s functioning. If treatment of other potential causes of the
BPSD is unsuccessful, antipsychotic medications can be considered,
taking into account their signiﬁcant risks compared with potential
beneﬁts. When an antipsychotic is used for BPSD, it is advisable to
obtain informed consent.
Item 5. Don’t routinely prescribe lipid-lowering medications in
individuals with a limited life expectancy.47e52
Rationale: There is no evidence that hypercholesterolemia or low
high-density lipoprotein cholesterol are important risk factors for all-
cause mortality, coronary heart disease mortality, or hospitalization
for myocardial infarction or unstable angina in persons older than
70 years. In fact, studies show that elderly patients with the lowest
cholesterol have the highest mortality after adjusting for other risk
factors. In addition, a less favorable risk-beneﬁt ratio may be seen for
patients older than 85, in whom beneﬁts may be more diminished
and risks from statin drugs more increased (cognitive impairment,
falls, neuropathy, and muscle damage).
Conclusion
It is AMDA’s goal that by identifying and disseminating these
selected items commonly used in the ﬁeld, whose necessity should be
questioned and discussed among both peers and patients/families,
that they can have an impact on how and when these are used to
ensure that the right care is delivered at the right time to the right
patient, in the right setting.
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